DOCSLIB.ORG

Review Article J Med Genet: First Published As 10.1136/Jmg.31.4.265 on 1 April 1994

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Review Article J Med Genet: First Published As 10.1136/Jmg.31.4.265 on 1 April 1994 JMed Genet 1994;31:265-279 265 Review article J Med Genet: first published as 10.1136/jmg.31.4.265 on 1 April 1994. Downloaded from The morbid anatomy of the human genome: chromosomal location of mutations causing disease (update 1 December 1993) Victor A McKusick, Joanna S Amberger A survey of the chromosomal location of Title - name of gene locus mutations causing genetic disorders was pub- MIM# - This is the number in McKusick's lished in this journal in January 1993 Mendelian inheritance in man (MIM, 10th ed, (McKusick and Amberger, 1993). The infor- 1992), its continuously updated online version mation presented then was complete to OMIM, and its periodically released CD- 1 November 1992. Here, we present informa- ROM version. (For historical reasons, the tion that has become available since that date, number may sometimes indicate location of including both new assignments and revision the entry in the "dominant catalogue" because of previous assignments. This information on the wild type gene was characterised and the so-called morbid anatomy of the human mapped before the recessive disorder resulting genome is derived from a synopsis of the from mutation at that site. The practice has human gene map that has been updated con- been to create only one entry in MIM for each tinuously since 1971 as part of McKusick's gene locus; however, for some disorders, an Mendelian inheritance in man (10th ed, 1992) entry describing the phenotype, identified by a and of OMIM (online Mendelian inheritance in number sign (#), and a separate entry, identi- man, available generally since 1987). fied by an asterisk, for the protein affected by In table 1, new information on genes that the mutation have been created. Marfan syn- have been located to specific chromosomal drome (154700) and fibrillin (134797) are positions and are also the site of disease-pro- examples; see chromosome 15.) ducing mutations is arranged by chromosome, http://jmg.bmj.com/ starting with chromosome 1 and with the end Method of mapping of the short arm of the chromosome in each A = in situ DNA-RNA or DNA-DNA case. The new information is presented in pic- annealing ("hybridisation"); for example, torial form in the figure. COL7A1 to 3p21.3 2. In table 2 an alphabetised list of these disor- C = chromosome mediated gene transfer ders and the chromosomal location of the (CMGT); for example, cotransfer of COLlAl mutation in each case are provided. After the and kinase thymidine gene on chromosome 17. on September 27, 2021 by guest. Protected copyright. name of the disorder, both in the "Disorder" Ch = chromosomal change associated with field of table 1 and in table 2, the numbers 1, particular phenotype and not proved to repre- 2, or 3 in parentheses indicate that its chromo- sent linkage (Fc), deletion (D), or virus effect somal location was determined by mapping of (V); for example, blepharophimosis, epican- the wild type gene (1), by mapping of the clin- thus inversus, and ptosis to 3q22-q23. ical phenotype (2), or by both strategies (3). D = deletion or dosage mapping (concur- (In some instances, a (3) is used when the rence of chromosomal deletion and phenotyp- clinical phenotype has been mapped and an ic evidence of hemizygosity), trisomy mapping intragenic mutation has been identified in a (presence of three alleles in the case of a highly candidate gene even though the wild type gene polymorphic locus), or gene dosage effects has not been independently mapped.) (correlation of trisomic state of part or all of a The fields in the listing by chromosome chromosome with 50% more gene product). (table 1) are as follows: Includes "loss of heterozygosity" (loss of alle- Location - that is, chromosomal site (p = les) in malignancies. Examples: acid phos- Center for Medical short arm; q = long arm; numbers = band; ter phatase-I to chromosome 2; glutathione Genetics, = end). reductase to chromosome 8. Includes DNA The Johns Hopkins Symbol - The symbol approved by the Hospital, dosage; for example, fibrinogen loci to 4q2. Blalock Building, Nomenclature Committee of the Human Dosage mapping also includes coamplification Room 1007, Gene Mapping Workshops and their successor in tumour cells. 600 N Wolfe Street, organisation is given first; alternative symbols F = linkage study in Baltimore, MD families; for example, 21287-4922, USA are included. linkage of ABO blood group and nail-patella VA McKusick Status - C = confirmed; P = provisional; L syndrome. When a chromosomal heteromor- J S Amberger = "in limbo" (that is, tentative or inconsis- phism or rearrangement is one trait, Fc is Correspondence to tent). The "in limbo" entries are not included used; for example, Duffy blood group locus J S Amberger in the figure. on chromosome 1. When one or both of the 266 McKusick, Amberger linked loci are identified by a DNA polymor- the number 2) that have been mapped only on phism, Fd is used; for example, Osler-Rendu- the basis of the clinical phenotype, which is Weber disease on chromosome 9q. F=L in found to be linked to markers at a particular the symbolism of the HGM workshops. chromosomal site or is found in association J Med Genet: first published as 10.1136/jmg.31.4.265 on 1 April 1994. Downloaded from H = based on presumed homology; for with a chromosomal aberration, include alkap- example, Neimann-Pick disease, type C, on tonuria, cartilage-hair hypoplasia, familial l9p. Mainly heuristic or confirmatory. dysautonomia, hereditary haemorrhagic LD = linkage disequilibrium; includes telangiectasia, and Werner syndrome. homozygosity mapping, for example, familial Rubinstein-Taybi syndrome was mapped on dysautonomia. the basis of a chromosomal aberration. The M = Microcell mediated gene transfer mapping information provides the starting (MMGT); for example, Bloom syndrome. point for isolating the mutant gene by posi- Psh = PCR of somatic cell hybrid DNA. tional cloning or the candidate gene approach. RE = Restriction endonuclease techniques; In the case of yet other disorders (labelled for example, physical linkage of 3 fibrinogen with the number 3) the clinical disorder and genes (on 4q) and apolipoprotein cluster, the wild type gene have been separately including APOC3 on 1 1q. mapped. These include instances in which the REa = combined with somatic cell hybridis- candidate gene approach has led to definition ation; for example, gene for type VII collagen of the basic defect in the clinical disorder. (COL7A1), which is mutant in dystrophic epi- Examples in the last year included familial dermolysis bullosa. amyotrophic lateral sclerosis, type I (wild type REb = combined with chromosome sorting; gene = SOD1), supravalvar aortic stenosis for example, thyroglobulin to 8q. (For this (wild type gene = elastin), stenosis of the method, using flow sorted chromosomes, W aqueduct of Sylvius (wild type gene = was the symbol adopted by the HGM work- LI CAM), X linked Charcot-Marie-Tooth shops.) disease (wild type gene = connexin-32), and REn = neighbour analysis in restriction X linked immunodeficiency with hyper-IgM fragments, for example, in pulsed-field gel (wild type gene = CD40 ligand). electrophoresis (PFGE); for example, protein Mapping of genetic disorders has shed light C inhibitor. on both allelism and non-allelism. Examples S = 'segregation' (cosegregation) of human of non-allelic genetic heterogeneity found or cellular traits and human chromosomes (or extended in the last year include the following: segments of chromosomes) in particular the number of distinguished types of Charcot- clones from interspecies somatic cell hybrids; Marie-Tooth disease were increased by the for example, GM2 ganglioside activator pro- mapping of forms to Ip and 8q; in addition to tein on chromosome 5. When with restriction the forms already mapped, two types of famil- enzyme, REa. ial hypertrophic cardiomyopathy were mapped Disorder - Allelic disorders are separated to chromosomes 15 and 11; a third form of http://jmg.bmj.com/ by semicolons. Brackets [] indicate a "non- spinocerebellar ataxia was located to chromo- disease", that is, a variation with no definite some 14; non-allelic heterogeneity in multiple adverse consequences. Braces { } indicate spe- exostoses and Wagner syndrome was estab- cific susceptibility or resistance with mono- lished by finding linkage in some families to genic basis. (1) = wild type gene mapped. (2) chromosome 8 or 12, respectively, but not in = disease phenotype mapped. (3) = both wild others. The practice is to assign a number to type gene and disease phenotype mapped (or the various types of a particular disorder as on September 27, 2021 by guest. Protected copyright. disease phenotype mapped and mutations they are defined; for example, CMH1-4 for identified in the wild type gene). the forms of hypertrophic cardiomyopathy. Mouse - Mouse chromosome carrying The number of forms of retinitis pigmentosa homologous gene. defined on the basis of linkage has now reached RP10. As soon as the nature of the Discussion gene that is mutated is identified, one can sub- With the additions made in the last year, a stitute for the number a designation such as total of 928 disorders have by now been "retinitis pigmentosa, rhodopsin-related" or assigned to specific chromosomes and, in most "retinitis pigmentosa, peripherin-related." instances, to specific regions of those chromo- Allelic series as the basis of phenotypic somes. (More than 50 other disorders are diversity, that is, allelic heterogeneity, is illus- known to be caused by mutations in genes on trated by pairs or sets of phenotypes such as the X chromosome but their regional location cystic fibrosis and congenital bilateral absence is not known and therefore they have not been of vas deferens (caused by mutation in the included in this count.) The 928 disorders are CFTR gene) and the some seven disorders distributed over 767 loci; many loci have more that have been related to mutations in the type than one allelic mutation producing distinct II collagen gene.
Load more

Recommended publications
  • Familial Nephropathy and Multiple Exostoses with Exostosin-1 (EXT1) Gene Mutation
    PATHOPHYSIOLOGY of the RENAL BIOPSY www.jasn.org Familial Nephropathy and Multiple Exostoses With Exostosin-1 (EXT1) Gene Mutation Ian S. D. Roberts* and Jonathan M. Gleadle† *Department of Cellular Pathology, John Radcliffe Hospital, Headley Way, Headington, Oxford, United Kingdom; and †Renal Unit, Level 6, Flinders Medical Centre, Bedford Park, South Australia, Australia ABSTRACT Glomerular deposition of fibrillar collagen is a characteristic finding of genetically mained in remission with trace protein- distinct conditions, including nail-patella syndrome and collagen type III glomeru- uria until cyclosporine was stopped 3.5 lopathy. A case of familial nephropathy in which steroid-sensitive nephrotic syn- yr later. Six months after this, she suf- drome and glomerular deposits of fibrillar collagen are associated with multiple fered another relapse of nephrotic exostoses due to mutation of the EXT1 gene is described. This gene encodes a syndrome that responded to 60 mg pred- glycosyltransferase required for synthesis of heparan sulfate glycosaminoglycans. nisolone and reintroduction of cyclo- There is deficiency of heparan sulfate and perlecan, together with accumulation of sporine. After a further relapse 18 mo collagens, in the matrix of EXT1-associated osteochondromas. Similar glomerular later and because of the development of basement membrane abnormalities could offer an explanation for both the renal adverse corticosteroid effects, she was ultrastructural changes and steroid-sensitive nephrotic syndrome. treated with a 2-mo course of cyclophos- phamide (2.5 mg/kg, orally). Ten years J Am Soc Nephrol 19: 450–453, 2008. doi: 10.1681/ASN.2007080842 after her initial presentation, she remains in full remission and off steroids. Renal function has remained normal through- A 37-yr-old woman presented with the history of renal disease and hearing im- out with a current serum creatinine of nephrotic syndrome.
    [Show full text]
  • Next Generation Sequencing Panels for Disorders of Sex Development
    Next Generation Sequencing Panels for Disorders of Sex Development Disorders of Sex Development – Overview Disorders of sex development (DSDs) occur when sex development does not follow the course of typical male or female patterning. Types of DSDs include congenital development of ambiguous genitalia, disjunction between the internal and external sex anatomy, incomplete development of the sex anatomy, and abnormalities of the development of gonads (such as ovotestes or streak ovaries) (1). Sex chromosome anomalies including Turner syndrome and Klinefelter syndrome as well as sex chromosome mosaicism are also considered to be DSDs. DSDs can be caused by a wide range of genetic abnormalities (2). Determining the etiology of a patient’s DSD can assist in deciding gender assignment, provide recurrence risk information for future pregnancies, and can identify potential health problems such as adrenal crisis or gonadoblastoma (1, 3). Sex chromosome aneuploidy and copy number variation are common genetic causes of DSDs. For this reason, chromosome analysis and/or microarray analysis typically should be the first genetic analysis in the case of a patient with ambiguous genitalia or other suspected disorder of sex development. Identifying whether a patient has a 46,XY or 46,XX karyotype can also be helpful in determining appropriate additional genetic testing. Abnormal/Ambiguous Genitalia Panel Our Abnormal/Ambiguous Genitalia Panel includes mutation analysis of 72 genes associated with both syndromic and non-syndromic DSDs. This comprehensive panel evaluates a broad range of genetic causes of ambiguous or abnormal genitalia, including conditions in which abnormal genitalia are the primary physical finding as well as syndromic conditions that involve abnormal genitalia in addition to other congenital anomalies.
    [Show full text]
  • CRISPR Screening of Porcine Sgrna Library Identifies Host Factors
    ARTICLE https://doi.org/10.1038/s41467-020-18936-1 OPEN CRISPR screening of porcine sgRNA library identifies host factors associated with Japanese encephalitis virus replication Changzhi Zhao1,5, Hailong Liu1,5, Tianhe Xiao1,5, Zichang Wang1, Xiongwei Nie1, Xinyun Li1,2, Ping Qian2,3, Liuxing Qin3, Xiaosong Han1, Jinfu Zhang1, Jinxue Ruan1, Mengjin Zhu1,2, Yi-Liang Miao 1,2, Bo Zuo1,2, ✉ ✉ Kui Yang4, Shengsong Xie 1,2 & Shuhong Zhao 1,2 1234567890():,; Japanese encephalitis virus (JEV) is a mosquito-borne zoonotic flavivirus that causes ence- phalitis and reproductive disorders in mammalian species. However, the host factors critical for its entry, replication, and assembly are poorly understood. Here, we design a porcine genome-scale CRISPR/Cas9 knockout (PigGeCKO) library containing 85,674 single guide RNAs targeting 17,743 protein-coding genes, 11,053 long ncRNAs, and 551 microRNAs. Subsequently, we use the PigGeCKO library to identify key host factors facilitating JEV infection in porcine cells. Several previously unreported genes required for JEV infection are highly enriched post-JEV selection. We conduct follow-up studies to verify the dependency of JEV on these genes, and identify functional contributions for six of the many candidate JEV- related host genes, including EMC3 and CALR. Additionally, we identify that four genes associated with heparan sulfate proteoglycans (HSPGs) metabolism, specifically those responsible for HSPGs sulfurylation, facilitate JEV entry into porcine cells. Thus, beyond our development of the largest CRISPR-based functional genomic screening platform for pig research to date, this study identifies multiple potentially vulnerable targets for the devel- opment of medical and breeding technologies to treat and prevent diseases caused by JEV.
    [Show full text]
  • Moderate the MAOA-L Allele Expression with CRISPR/Cas9 System
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 23 April 2018 doi:10.20944/preprints201804.0275.v1 1 Review 2 Moderate the MAOA-L Allele Expression with CRISPR/Cas9 System 3 Martin L. Nelwan 4 Department of Animal Science – Other 5 Nelwan Institution for Human Resource Development 6 Jl. A. Yani No. 24 7 Palu, Sulawesi Tengah, Indonesia 8 Email: [email protected] 9 Abstract: Antisocial behavior is a behavior disorder inherited according to the inheritance of X-linked 10 chromosome. Mutations in the MAOA gene can cause different behaviors in humans. These can comprise 11 violent behavior or antisocial behavior. Low MAOA (MAOA-L) allele activity can cause antisocial 12 behavior in both healthy and unhealthy people. Antisocial from healthy males can originate from 13 maltreatment during childhood. There are no drugs for the treatment of antisocial behavior permanently 14 at this time. MAOA inhibitor can reverse antisocial behavior in animal models. To cure antisocial 15 behavior in the future, the CRISPR/Cas9 system in combination with iPSCs or ssODN methods for 16 instance can be used. This system has succeeded to correct erroneous segments in the F8 gene and F9 17 gene. Both genes occupy the X chromosome. The MAOA gene also occupies the X chromosome. It seems 18 that CRISPR/Cas9 system may be a beneficial tool to edit erroneous segments in the MAOA gene to treat 19 antisocial behavior. 20 Keywords: advanced therapy, aggressive, antisocial, behavior, MAOA. 21 22 1. Introduction 23 Antisocial behavior is a hereditary disorder inherited through an X-linked recessive inheritance 24 pattern.
    [Show full text]
  • Selectin Ligand Sialyl-Lewis X Antigen Drives Metastasis of Hormone-Dependent Breast Cancers
    Published OnlineFirst October 24, 2011; DOI: 10.1158/0008-5472.CAN-11-1139 Cancer Tumor and Stem Cell Biology Research Selectin Ligand Sialyl-Lewis x Antigen Drives Metastasis of Hormone-Dependent Breast Cancers Sylvain Julien1, Aleksandar Ivetic2, Anita Grigoriadis3, Ding QiZe1, Brian Burford1, Daisy Sproviero1, Gianfranco Picco1, Cheryl Gillett4, Suzanne L. Papp5, Lana Schaffer5, Andrew Tutt3, Joyce Taylor-Papadimitriou1, Sarah E. Pinder4, and Joy M. Burchell1 Abstract The glycome acts as an essential interface between cells and the surrounding microenvironment. However, changes in glycosylation occur in nearly all breast cancers, which can alter this interaction. Here, we report that profiles of glycosylation vary between ER-positive and ER-negative breast cancers. We found that genes involved in the synthesis of sialyl-Lewis x (sLex; FUT3, FUT4, and ST3GAL6) are significantly increased in estrogen receptor alpha-negative (ER-negative) tumors compared with ER-positive ones. SLex expression had no influence on the survival of patients whether they had ER-negative or ER-positive tumors. However, high expression of sLex in ER- positive tumors was correlated with metastasis to the bone where sLex receptor E-selectin is constitutively expressed. The ER-positive ZR-75-1 and the ER-negative BT20 cell lines both express sLex but only ZR-75-1 cells could adhere to activated endothelial cells under dynamic flow conditions in a sLex and E-selectin–dependent manner. Moreover, L/P-selectins bound strongly to ER-negative MDA-MB-231 and BT-20 cell lines in a heparan sulfate (HS)–dependent manner that was independent of sLex expression. Expression of glycosylation genes involved in heparan biosynthesis (EXT1 and HS3ST1) was increased in ER-negative tumors.
    [Show full text]
  • The Genetic Basis for Skeletal Diseases
    insight review articles The genetic basis for skeletal diseases Elazar Zelzer & Bjorn R. Olsen Harvard Medical School, Department of Cell Biology, 240 Longwood Avenue, Boston, Massachusetts 02115, USA (e-mail: [email protected]) We walk, run, work and play, paying little attention to our bones, their joints and their muscle connections, because the system works. Evolution has refined robust genetic mechanisms for skeletal development and growth that are able to direct the formation of a complex, yet wonderfully adaptable organ system. How is it done? Recent studies of rare genetic diseases have identified many of the critical transcription factors and signalling pathways specifying the normal development of bones, confirming the wisdom of William Harvey when he said: “nature is nowhere accustomed more openly to display her secret mysteries than in cases where she shows traces of her workings apart from the beaten path”. enetic studies of diseases that affect skeletal differentiation to cartilage cells (chondrocytes) or bone cells development and growth are providing (osteoblasts) within the condensations. Subsequent growth invaluable insights into the roles not only of during the organogenesis phase generates cartilage models individual genes, but also of entire (anlagen) of future bones (as in limb bones) or membranous developmental pathways. Different mutations bones (as in the cranial vault) (Fig. 1). The cartilage anlagen Gin the same gene may result in a range of abnormalities, are replaced by bone and marrow in a process called endo- and disease ‘families’ are frequently caused by mutations in chondral ossification. Finally, a process of growth and components of the same pathway.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • A Proteomic Approach to Uncover Neuroprotective Mechanisms of Oleocanthal Against Oxidative Stress
    International Journal of Molecular Sciences Article A Proteomic Approach to Uncover Neuroprotective Mechanisms of Oleocanthal against Oxidative Stress Laura Giusti 1,†, Cristina Angeloni 2,†, Maria Cristina Barbalace 3, Serena Lacerenza 4, Federica Ciregia 5, Maurizio Ronci 6 ID , Andrea Urbani 7, Clementina Manera 4, Maria Digiacomo 4 ID , Marco Macchia 4, Maria Rosa Mazzoni 4, Antonio Lucacchini 1 ID and Silvana Hrelia 3,* ID 1 Department of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy; [email protected] (L.G.); [email protected] (A.L.) 2 School of Pharmacy, University of Camerino, 62032 Camerino, Italy; [email protected] 3 Department for Life Quality Studies, Alma Mater Studiorum, University of Bologna, 47921 Rimini, Italy; [email protected] 4 Department of Pharmacy, University of Pisa, 56126 Pisa, Italy; [email protected] (S.L.); [email protected] (C.M.); [email protected] (M.D.); [email protected] (M.M.); [email protected] (M.R.M.) 5 Department of Rheumatology, GIGA Research, Centre Hospitalier Universitaire (CHU) de Liège, University of Liège, 4000 Liège, Belgium; [email protected] 6 Department of Medical, Oral and Biotechnological Sciences, University G. d’Annunzio of Chieti-Pescara, 65127 Pescara, Italy; [email protected] 7 Institute of Biochemistry and Clinical Biochemistry, Catholic University, 00198 Rome, Italy; [email protected] * Correspondence: [email protected]; Tel.: +39-051-209-1235 † These authors contributed equally to this work. Received: 3 July 2018; Accepted: 1 August 2018; Published: 8 August 2018 Abstract: Neurodegenerative diseases represent a heterogeneous group of disorders that share common features like abnormal protein aggregation, perturbed Ca2+ homeostasis, excitotoxicity, impairment of mitochondrial functions, apoptosis, inflammation, and oxidative stress.
    [Show full text]
  • Genes in Eyecare Geneseyedoc 3 W.M
    Genes in Eyecare geneseyedoc 3 W.M. Lyle and T.D. Williams 15 Mar 04 This information has been gathered from several sources; however, the principal source is V. A. McKusick’s Mendelian Inheritance in Man on CD-ROM. Baltimore, Johns Hopkins University Press, 1998. Other sources include McKusick’s, Mendelian Inheritance in Man. Catalogs of Human Genes and Genetic Disorders. Baltimore. Johns Hopkins University Press 1998 (12th edition). http://www.ncbi.nlm.nih.gov/Omim See also S.P.Daiger, L.S. Sullivan, and B.J.F. Rossiter Ret Net http://www.sph.uth.tmc.edu/Retnet disease.htm/. Also E.I. Traboulsi’s, Genetic Diseases of the Eye, New York, Oxford University Press, 1998. And Genetics in Primary Eyecare and Clinical Medicine by M.R. Seashore and R.S.Wappner, Appleton and Lange 1996. M. Ridley’s book Genome published in 2000 by Perennial provides additional information. Ridley estimates that we have 60,000 to 80,000 genes. See also R.M. Henig’s book The Monk in the Garden: The Lost and Found Genius of Gregor Mendel, published by Houghton Mifflin in 2001 which tells about the Father of Genetics. The 3rd edition of F. H. Roy’s book Ocular Syndromes and Systemic Diseases published by Lippincott Williams & Wilkins in 2002 facilitates differential diagnosis. Additional information is provided in D. Pavan-Langston’s Manual of Ocular Diagnosis and Therapy (5th edition) published by Lippincott Williams & Wilkins in 2002. M.A. Foote wrote Basic Human Genetics for Medical Writers in the AMWA Journal 2002;17:7-17. A compilation such as this might suggest that one gene = one disease.
    [Show full text]
  • Congenital Disorders of Glycosylation from a Neurological Perspective
    brain sciences Review Congenital Disorders of Glycosylation from a Neurological Perspective Justyna Paprocka 1,* , Aleksandra Jezela-Stanek 2 , Anna Tylki-Szyma´nska 3 and Stephanie Grunewald 4 1 Department of Pediatric Neurology, Faculty of Medical Science in Katowice, Medical University of Silesia, 40-752 Katowice, Poland 2 Department of Genetics and Clinical Immunology, National Institute of Tuberculosis and Lung Diseases, 01-138 Warsaw, Poland; [email protected] 3 Department of Pediatrics, Nutrition and Metabolic Diseases, The Children’s Memorial Health Institute, W 04-730 Warsaw, Poland; [email protected] 4 NIHR Biomedical Research Center (BRC), Metabolic Unit, Great Ormond Street Hospital and Institute of Child Health, University College London, London SE1 9RT, UK; [email protected] * Correspondence: [email protected]; Tel.: +48-606-415-888 Abstract: Most plasma proteins, cell membrane proteins and other proteins are glycoproteins with sugar chains attached to the polypeptide-glycans. Glycosylation is the main element of the post- translational transformation of most human proteins. Since glycosylation processes are necessary for many different biological processes, patients present a diverse spectrum of phenotypes and severity of symptoms. The most frequently observed neurological symptoms in congenital disorders of glycosylation (CDG) are: epilepsy, intellectual disability, myopathies, neuropathies and stroke-like episodes. Epilepsy is seen in many CDG subtypes and particularly present in the case of mutations
    [Show full text]
  • Mutations Within Or Upstream of the Basic Helixð Loopð Helix Domain of the TWIST Gene Are Specific to Saethre-Chotzen Syndrome
    European Journal of Human Genetics (1999) 7, 27–33 © 1999 Stockton Press All rights reserved 1018–4813/99 $12.00 t http://www.stockton-press.co.uk/ejhg ARTICLES Mutations within or upstream of the basic helix–loop–helix domain of the TWIST gene are specific to Saethre-Chotzen syndrome Vincent El Ghouzzi, Elisabeth Lajeunie, Martine Le Merrer, Val´erie Cormier-Daire, Dominique Renier, Arnold Munnich and Jacky Bonaventure Unit´e de Recherches sur les Handicaps G´en´etiques de l’Enfant, Institut Necker, Paris, France Saethre-Chotzen syndrome (ACS III) is an autosomal dominant craniosynostosis syndrome recently ascribed to mutations in the TWIST gene, a basic helix–loop–helix (b-HLH) transcription factor regulating head mesenchyme cell development during cranial neural tube formation in mouse. Studying a series of 22 unrelated ACS III patients, we have found TWIST mutations in 16/22 cases. Interestingly, these mutations consistently involved the b-HLH domain of the protein. Indeed, mutant genotypes included frameshift deletions/insertions, nonsense and missense mutations, either truncating or disrupting the b-HLH motif of the protein. This observation gives additional support to the view that most ACS III cases result from loss-of-function mutations at the TWIST locus. The P250R recurrent FGFR 3 mutation was found in 2/22 cases presenting mild clinical manifestations of the disease but 4/22 cases failed to harbour TWIST or FGFR 3 mutations. Clinical re-examination of patients carrying TWIST mutations failed to reveal correlations between the mutant genotype and severity of the phenotype. Finally, since no TWIST mutations were detected in 40 cases of isolated coronal craniosynostosis, the present study suggests that TWIST mutations are specific to Saethre- Chotzen syndrome.
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]